Compare Stocks

→ Urgent Nvidia Warning (From Altimetry) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALT Altimmune	$7.30 +1.5%	$9.11	$2.09 ▼ $14.84	$517.50M	0.22	3.04 million shs	2.02 million shs
AMT American Tower	$181.74 +1.2%	$189.15	$154.58 ▼ $219.10	$84.75B	0.71	2.88 million shs	3.13 million shs

The Best High-Yield Dividend Stocks for 2024

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALT Altimmune	+1.53%	+0.55%	-21.42%	-21.67%	+46.59%
AMT American Tower	+1.17%	+5.90%	-5.49%	-6.07%	-5.32%

Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share (Ad)

The latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty.

See why the elites are pouring billions into gold.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALT Altimmune	0.8813 of 5 stars	3.3	1.0	0.0	0.0	1.8	1.7	0.0
AMT American Tower	4.881 of 5 stars	3.5	5.0	2.5	3.1	2.6	2.5	1.9

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALT Altimmune	2.50	Moderate Buy	$15.00	105.48% Upside
AMT American Tower	2.91	Moderate Buy	$221.91	22.10% Upside

Current Analyst Ratings

Latest CYC, ADR, AMT, and ALT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/1/2024	AMT American Tower	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Outperform ➝ Sector Outperform	$243.00 ➝ $223.00
5/1/2024	AMT American Tower	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$228.00 ➝ $220.00
5/1/2024	AMT American Tower	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Outperform ➝ Strong-Buy	$226.00 ➝ $248.00
4/29/2024	ALT Altimmune	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral
4/15/2024	AMT American Tower	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$183.00 ➝ $196.00
4/8/2024	AMT American Tower	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral	$205.00
4/1/2024	ALT Altimmune	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$15.00 ➝ $12.00
3/28/2024	ALT Altimmune	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
3/5/2024	AMT American Tower	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$224.00 ➝ $234.00
2/28/2024	AMT American Tower	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$235.00 ➝ $228.00
2/28/2024	AMT American Tower	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$236.00 ➝ $230.00

(Data available from 5/4/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALT Altimmune	$430K	1,203.48	N/A	N/A	$2.75 per share	2.65
AMT American Tower	$11.14B	7.61	$10.02 per share	18.13	$22.86 per share	7.95

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALT Altimmune	-$88.45M	-$1.65	N/A	N/A	N/A	-20,780.75%	-44.77%	-40.72%	5/9/2024 (Confirmed)
AMT American Tower	$1.48B	$4.42	41.12	17.61	1.42	18.42%	18.45%	3.11%	7/25/2024 (Estimated)

Latest CYC, ADR, AMT, and ALT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/9/2024	N/A	ALT Altimmune	-$0.36	N/A	+$0.36	N/A	N/A	N/A
4/30/2024	Q1 2024	AMT American Tower	$2.43	$1.96	-$0.47	$1.96	$2.79 billion	$2.83 billion
3/27/2024	Q4 2023	ALT Altimmune	-$0.35	-$0.33	+$0.02	-$0.12	N/A	$0.04 million
2/27/2024	12/31/2023	AMT American Tower	$2.10	$0.94	-$1.16	$0.18	$2.74 billion	$2.79 billion

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALT Altimmune	N/A	N/A	N/A	N/A	N/A
AMT American Tower	$6.48	3.57%	+12.50%	146.61%	N/A

Latest CYC, ADR, AMT, and ALT Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
3/14/2024	AMT American Tower	quarterly	$1.62	3.3%	4/11/2024	4/12/2024	4/26/2024

(Data available from 1/1/2013 forward)

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALT Altimmune	N/A	17.26	17.26
AMT American Tower	3.39	0.85	0.69

Ownership

Institutional Ownership

Company	Institutional Ownership
ALT Altimmune	78.05%
AMT American Tower	92.69%

Insider Ownership

Company	Insider Ownership
ALT Altimmune	4.10%
AMT American Tower	0.18%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
ALT Altimmune	59	70.89 million	67.99 million	Optionable
AMT American Tower	5,643	466.35 million	465.51 million	Optionable

CYC, ADR, AMT, and ALT Headlines

Source	Headline
	American Tower Co. (NYSE:AMT) Shares Bought by Los Angeles Capital Management LLC marketbeat.com - May 4 at 10:25 AM
	Perfect Pullback Play with a Safe 8.4% Payout marketbeat.com - May 3 at 10:01 PM
	American Tower Co. (NYSE:AMT) Shares Sold by Fisher Asset Management LLC marketbeat.com - May 3 at 6:13 PM
	Raymond James Upgrades American Tower (NYSE:AMT) to "Strong-Buy" americanbankingnews.com - May 3 at 6:20 AM
	BMO Capital Markets Lowers American Tower (NYSE:AMT) Price Target to $220.00 americanbankingnews.com - May 3 at 5:32 AM
	Loring Wolcott & Coolidge Fiduciary Advisors LLP MA Has $288.53 Million Position in American Tower Co. (NYSE:AMT) marketbeat.com - May 2 at 9:52 PM
	Raymond James Upgrades American Tower (AMT) msn.com - May 2 at 8:12 PM
	American Tower (NYSE:AMT) Price Target Lowered to $223.00 at Scotiabank americanbankingnews.com - May 2 at 7:20 AM
	What the Options Market Tells Us About American Tower benzinga.com - May 1 at 7:12 PM
	American Tower (AMT) Q1 2024 Earnings Call Transcript fool.com - May 1 at 7:12 PM
	New York Life Investment Management LLC Buys 32,392 Shares of American Tower Co. (NYSE:AMT) marketbeat.com - May 1 at 5:46 PM
	Scotiabank Trims American Tower (NYSE:AMT) Target Price to $223.00 marketbeat.com - May 1 at 4:33 PM
	American Tower inches higher after Raymond James upgrades on growth prospects msn.com - May 1 at 2:12 PM
	American Tower Corporation (NYSE:AMT) Q1 2024 Earnings Call Transcript finance.yahoo.com - May 1 at 2:12 PM
	REITs Continue To Clobber Q1 Estimates finance.yahoo.com - May 1 at 2:12 PM
	American Tower: Strong Q1 Performance and Positive Growth Trajectory Justify Buy Rating markets.businessinsider.com - May 1 at 9:11 AM
	The Analyst Landscape: 6 Takes On American Tower markets.businessinsider.com - May 1 at 9:11 AM
	American Tower Corp (AMT) Q1 2024 Earnings Call Transcript Highlights: Strong Performance and ... finance.yahoo.com - May 1 at 9:11 AM
	American Tower (NYSE:AMT) Announces Earnings Results marketbeat.com - May 1 at 8:55 AM
	American Tower (NYSE:AMT) Raised to Strong-Buy at Raymond James marketbeat.com - May 1 at 7:16 AM
	Q1 2024 American Tower Corp Earnings Call finance.yahoo.com - May 1 at 1:54 AM
	Alpha Cubed Investments LLC Increases Stock Holdings in American Tower Co. (NYSE:AMT) marketbeat.com - April 30 at 7:31 PM
	American Tower's (AMT) Q1 AFFO Beat Estimates, '24 View Raised zacks.com - April 30 at 1:20 PM
	American Tower Delivers Robust Q1 Performance, Eyes Long-Term Growth Despite Market Challenges benzinga.com - April 30 at 12:01 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

High-Yield Texas Instruments Could Hit New Highs Soon
April 24, 2024 11:27 AM
View High-Yield Texas Instruments Could Hit New Highs Soon
Wendy’s Stock Could Be Your Best Passive Income Stock
April 9, 2024 7:45 AM
View Wendy’s Stock Could Be Your Best Passive Income Stock
Predicting a Bear Market: 7 Signs and Why it's Tough to Do
April 17, 2024 12:00 PM
View Predicting a Bear Market: 7 Signs and Why it's Tough to Do
Institutions Think This Consumer Stock Could Break Higher
April 8, 2024 9:40 AM
View Institutions Think This Consumer Stock Could Break Higher
Goldman Boosted FMC Stock’s Price Targets, Setting Up a Breakout
May 1, 2024 7:38 AM
View Goldman Boosted FMC Stock’s Price Targets, Setting Up a Breakout

All Headlines

Company Descriptions

Altimmune

NASDAQ:ALT

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.

American Tower

NYSE:AMT

American Tower, one of the largest global REITs, is a leading independent owner, operator and developer of multitenant communications real estate with a portfolio of over 224,000 communications sites and a highly interconnected footprint of U.S. data center facilities.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial